Fort Sheridan Advisors LLC Trims Stock Holdings in CVS Health Corporation (NYSE:CVS)

Fort Sheridan Advisors LLC decreased its stake in CVS Health Corporation (NYSE:CVS - Free Report) by 60.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,319 shares of the pharmacy operator's stock after selling 5,130 shares during the quarter. Fort Sheridan Advisors LLC's holdings in CVS Health were worth $225,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of CVS. McIlrath & Eck LLC increased its position in CVS Health by 32.6% in the fourth quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock worth $32,000 after buying an additional 174 shares in the last quarter. Park Square Financial Group LLC bought a new position in shares of CVS Health in the fourth quarter worth about $43,000. PARK CIRCLE Co boosted its stake in shares of CVS Health by 42.9% in the fourth quarter. PARK CIRCLE Co now owns 1,000 shares of the pharmacy operator's stock worth $45,000 after acquiring an additional 300 shares during the period. Strategic Investment Solutions Inc. IL boosted its stake in shares of CVS Health by 77.2% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 1,024 shares of the pharmacy operator's stock worth $46,000 after acquiring an additional 446 shares during the period. Finally, Ball & Co Wealth Management Inc. bought a new position in shares of CVS Health in the fourth quarter worth about $49,000. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health Trading Down 1.4%

Shares of NYSE:CVS traded down $0.89 during trading on Friday, hitting $64.73. The company had a trading volume of 7,020,831 shares, compared to its average volume of 10,806,408. The stock has a market cap of $81.88 billion, a price-to-earnings ratio of 15.45, a price-to-earnings-growth ratio of 0.93 and a beta of 0.57. CVS Health Corporation has a one year low of $43.56 and a one year high of $72.51. The company has a fifty day simple moving average of $65.05 and a two-hundred day simple moving average of $62.35. The company has a debt-to-equity ratio of 0.77, a current ratio of 0.82 and a quick ratio of 0.63.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.63. The business had revenue of $94.59 billion during the quarter, compared to analyst estimates of $93.07 billion. CVS Health had a return on equity of 10.59% and a net margin of 1.39%. The company's revenue for the quarter was up 7.0% on a year-over-year basis. During the same period last year, the company earned $1.31 EPS. As a group, equities analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Tuesday, July 22nd will be issued a $0.665 dividend. The ex-dividend date of this dividend is Tuesday, July 22nd. This represents a $2.66 annualized dividend and a dividend yield of 4.11%. CVS Health's payout ratio is 63.48%.

Insider Buying and Selling at CVS Health

In other CVS Health news, Director Guy P. Sansone purchased 1,570 shares of CVS Health stock in a transaction dated Thursday, June 5th. The shares were purchased at an average cost of $63.70 per share, for a total transaction of $100,009.00. Following the completion of the acquisition, the director owned 12,007 shares in the company, valued at $764,845.90. This represents a 15.04% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.22% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Jefferies Financial Group upped their price objective on CVS Health from $74.00 to $80.00 and gave the stock a "buy" rating in a research note on Monday, June 30th. Robert W. Baird upped their price objective on CVS Health from $51.00 to $71.00 and gave the stock a "neutral" rating in a research note on Tuesday, April 15th. Barclays set a $79.00 price objective on CVS Health and gave the stock an "overweight" rating in a research note on Monday, June 2nd. Piper Sandler increased their price target on CVS Health from $72.00 to $74.00 and gave the company an "overweight" rating in a research note on Friday, March 21st. Finally, UBS Group increased their price target on CVS Health from $67.00 to $71.00 and gave the company a "neutral" rating in a research note on Friday, May 2nd. Two equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $75.06.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.